Question 1

Does Citadel Advisors own BRNS stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Citadel Advisors holds 76,754 shares of BRNS (Barinthus Biotherapeutics PL), worth $50,658.

Question 2

How many shares of BRNS does Citadel Advisors own?

Accepted Answer

As of its Q2 2026 13F, Citadel Advisors holds 76,754 shares of BRNS (Barinthus Biotherapeutics PL).

Question 3

What is Citadel Advisors' BRNS position worth?

Accepted Answer

As of its Q2 2026 13F, Citadel Advisors' BRNS position is worth $50,658.

Question 4

Is Citadel Advisors buying or selling BRNS?

Accepted Answer

In Q2 2026, Citadel Advisors reduced its BRNS position by 42,242 shares (-35.5%).

Question 5

When did Citadel Advisors first buy BRNS?

Accepted Answer

Citadel Advisors first reported BRNS in its Q4 2022 13F and has listed it in 9 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	76,754	-35.5%	$50,658	0.0%	$0.66	0
2026-Q1	Increased	118,996	+0.2%	$68,125	0.0%	—	14
2025-Q4	New	118,799	-	$83,171	0.0%	—	33
2025-Q3	Exited	0	-100.0%	$0	0.0%	—	0
2025-Q2	Decreased	16,227	-38.0%	$14,770	0.0%	—	0
2025-Q1	New	26,172	-	$25,910	0.0%	—	29
2024-Q4	Exited	0	-100.0%	$0	0.0%	—	0
2024-Q3	Increased	27,717	+72.8%	$34,092	0.0%	—	20